Year: 2017-18

Company: Luminex Corporation

Liaison(s): Rohit Amarshi, Atherine Dolom, Ilona Kravtsova, Urvi Mehta, Ana Mena, Crystal Wu

Luminex Corporation is biotechnology company based out of Austin, Texas. Luminex develops, manufactures and markets proprietary biological testing technologies with applications in life sciences. Luminex is looking to expand their presence in the global molecular diagnostic (MDx) market with their distinct sample-to-answer platforms: 1. Aries: a fully automated sample-to-answer PCR-platform, capable of fully multiplexing up to 12 targets per sample. 2. Verigene II: A rapid, sample-to-answer platform, capable of very high multiplexing. Luminex requested the KGI team to research healthcare policy and understand why certain health care policy is important.

The Luminex Team Master’s Project reviewed the impact of healthcare policies on clinical guideline development in China, UK, Germany, and Japan. The project focused on disease states and treatment guidelines from the following therapeutic areas: respiratory, gastrointestinal, infectious disease (blood stream), and women’s health. The team conducted primary and secondary research to identify healthcare policies and map clinical guideline development from professional societies of all four countries mentioned above. The team will report on industry best practices, analyze KOL interviews, identify areas that need improvement in guidelines, and a comprehensive methodology for international KOL engagement.